Psychedelic Drugs Market Set To Grow By 1.37B By 2028, Driven By Mental Health Disorders And AI Integration
CMPS Stock | USD 4.58 0.17 3.58% |
Slightly above 62% of Compass Pathways' investor base is looking to short. The analysis of overall sentiment of trading Compass Pathways Plc stock suggests that many investors are alarmed at this time. Compass Pathways' investing sentiment can be driven by a variety of factors including economic data, Compass Pathways' earnings reports, geopolitical events, and overall market trends.
Compass |
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Read at benzinga.com
Compass Pathways Fundamental Analysis
We analyze Compass Pathways' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Pathways using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Pathways based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Compass Pathways is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Compass Pathways Plc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Compass Pathways stock to make a market-neutral strategy. Peer analysis of Compass Pathways could also be used in its relative valuation, which is a method of valuing Compass Pathways by comparing valuation metrics with similar companies.
Peers
Compass Pathways Related Equities
AGL | Agilon Health | 4.37 | ||||
PNTG | Pennant | 3.46 | ||||
ADUS | Addus HomeCare | 0.89 | ||||
DVA | DaVita HealthCare | 0.77 | ||||
ACHC | Acadia Healthcare | 0.62 | ||||
ENSG | Ensign | 0.60 | ||||
SGRY | Surgery Partners | 0.54 | ||||
AMED | Amedisys | 0.15 | ||||
CCRN | Cross Country | 0.05 | ||||
USPH | US Physicalrapy | 0.10 | ||||
EHAB | Enhabit | 0.77 | ||||
FSNUY | Fresenius | 0.79 | ||||
INNV | InnovAge Holding | 3.15 | ||||
NHC | National HealthCare | 3.24 |
Additional Tools for Compass Stock Analysis
When running Compass Pathways' price analysis, check to measure Compass Pathways' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Pathways is operating at the current time. Most of Compass Pathways' value examination focuses on studying past and present price action to predict the probability of Compass Pathways' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Pathways' price. Additionally, you may evaluate how the addition of Compass Pathways to your portfolios can decrease your overall portfolio volatility.